leukemic DC by the use of the described cytokine cocktail. More importantly, by culturing AML blasts with the CI A23187 and IL-4 for only 2 days, we generated mature functionally active leukemic DC in 10 out of 15 CD14
À AML samples tested (Table 1) . Recently, we have shown that serum-free culture of AML-DC is feasible and that these DC are comparable to serum-enriched cultured AML-DC with regard to morphological, immunophenotypical and functional characteristics. 5 Overall, these results indicate that the serum-free culture of AML-DC derived from CD14 À AML blasts, by the use of CI, is feasible in 71% of the AML patients. The use of CI provides an excellent alternative method for the induction of DC differentiation in CD14
À AML samples, thus enabling the development of vaccination programs for this subgroup of AML patients. 
TO THE EDITOR
In a recent issue of Leukemia, 1,2 we have reported that dendritic cells (DC) generated from acute myeloid leukemia (AML) patients in the presence of GM-CSF, IL-4 and matured with CD40L can be obtained from two major precursors: DC derived from CD14+ leukemic cells and/or leukemic DC derived from the previously described in vivo expanded circulating blood myeloid DC (MDC). 3 Leukemic DC of both subsets exhibited DC morphology, had a phenotype of mature DC (CD83+), and could induce a potent proliferative response of naive CD4+ T cells. Moreover, both subsets produced large amounts of bioactive IL-12p70. 1 Interestingly, in accordance with our findings, van de Loosdrecht et al 4 also observed a correlation between the percentage of CD14 expression on AML blasts and leukemic DC yield (although defined by the expression of nonspecific DC markers such as CD40 and CD86). 
